Human Insulin Market by Therapeutics, Diagnostics, Patent, and Drugs Policy
The global market generated a revenue of $42.9 billion in 2017, and it is expected to witness a CAGR of 8.8% during the forecast period (2018–2023).
By: P&S Intelligence
In a recent P&S Intelligence research, the human insulin market (https://www.psmarketresearch.com/
Looking at the market growth, the human insulin market players, in order to increase their profits, are joining hands with one another through partnerships and collaborations. For instance, in August 2018, Ypsomed AG entered into a partnership with JRDF. Under the terms of the agreement, JRDF will contribute financial resources to help Ypsomed AG ramp up the development of its next-generation, fully-interoperable myLife YpsoPump. Similarly, in October 2018, Koninklijke Philips N.V. (Philips) collaborated with Ypsomed AG to develop digital monitoring services for self-medication adherence, based on Philips' HealthSuite digital platform and Ypsomed's connected devices.